{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-108839","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.912689+00:00","generated_at":"2026-05-16T22:38:24.629365+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ArriVent reports Q3 net loss $130.8M; cash $305.4M funds into mid-2027","bullets":["Net loss $130.8M for nine months ended Sep 30, 2025, up from $59.9M in 2024, driven by R&D spend including $40M upfront for ARR-217.","Cash and investments $305.4M as of Sep 30, 2025; expected to fund operations into mid-2027.","R&D expense $121.2M (incl. $40M upfront for ARR-217 license) vs $58.8M prior year; G&A $17.5M vs $11.8M.","Appointed Brent S. Rice as Chief Commercial Officer; Phase 1b firmonertinib data in EGFR PACC mutant NSCLC presented at WCLC.","Phase 3 ALPACCA trial for PACC mutant NSCLC first patient enrollment expected Q4 2025; topline FURVENT Phase 3 data in exon 20 insertion NSCLC projected early 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-108839","json":"https://secwatch.observer/filing/0001104659-25-108839.json","markdown":"https://secwatch.observer/filing/0001104659-25-108839.md","text":"https://secwatch.observer/filing/0001104659-25-108839.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/0001104659-25-108839-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925108839/avbp-20251110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:38:24.629365+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}